Ncardia Launches Cellistic, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today
Ncardia has launched a new business, Cellistic, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia's
Source: finanznachrichten.de